[go: up one dir, main page]

LT4214240T - Anti-ccr8 antikūnai - Google Patents

Anti-ccr8 antikūnai

Info

Publication number
LT4214240T
LT4214240T LTEPPCT/US2022/074214T LTUS2022074214T LT4214240T LT 4214240 T LT4214240 T LT 4214240T LT US2022074214 T LTUS2022074214 T LT US2022074214T LT 4214240 T LT4214240 T LT 4214240T
Authority
LT
Lithuania
Prior art keywords
ccr8 antibodies
ccr8
antibodies
Prior art date
Application number
LTEPPCT/US2022/074214T
Other languages
English (en)
Inventor
Andrew Mccluskey
Amanda SCHMIDT PAUSTIAN
Jane SEAGAL
Julie WILSBACHER
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of LT4214240T publication Critical patent/LT4214240T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LTEPPCT/US2022/074214T 2021-07-27 2022-07-27 Anti-ccr8 antikūnai LT4214240T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163226118P 2021-07-27 2021-07-27
PCT/US2022/074214 WO2023010054A1 (en) 2021-07-27 2022-07-27 Anti-ccr8 antibodies

Publications (1)

Publication Number Publication Date
LT4214240T true LT4214240T (lt) 2024-11-25

Family

ID=82898810

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2022/074214T LT4214240T (lt) 2021-07-27 2022-07-27 Anti-ccr8 antikūnai

Country Status (25)

Country Link
US (1) US11639393B2 (lt)
EP (2) EP4491635A2 (lt)
JP (1) JP7638935B2 (lt)
KR (1) KR20240067052A (lt)
CN (1) CN117425677A (lt)
AR (1) AR126578A1 (lt)
AU (1) AU2022317803A1 (lt)
BR (1) BR112023024837A2 (lt)
CA (1) CA3220121A1 (lt)
CO (1) CO2023015915A2 (lt)
DK (1) DK4214240T3 (lt)
ES (1) ES2995868T3 (lt)
FI (1) FI4214240T3 (lt)
HR (1) HRP20241561T1 (lt)
HU (1) HUE069018T2 (lt)
IL (1) IL307533A (lt)
LT (1) LT4214240T (lt)
MX (1) MX2023014154A (lt)
PL (1) PL4214240T3 (lt)
PT (1) PT4214240T (lt)
RS (1) RS66234B1 (lt)
SI (1) SI4214240T1 (lt)
SM (1) SMT202400483T1 (lt)
TW (1) TW202321304A (lt)
WO (1) WO2023010054A1 (lt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
WO2024165470A1 (en) 2023-02-06 2024-08-15 Bayer Aktiengesellschaft Combinations of dgk (diacylglycerol kinase) inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
US10087259B1 (en) 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
WO2017198631A1 (en) 2016-05-16 2017-11-23 Istituto Nazionale Di Genetica Molecolare - Ingm Markers selectively deregulated in tumor-infiltrating regulatory t cells
WO2018112033A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs
CA3057274C (en) 2017-03-29 2023-10-10 Shionogi & Co., Ltd. Pharmaceutical composition for cancer treatment
CA3124332A1 (en) * 2018-12-27 2020-07-02 Shionogi & Co., Ltd. Novel anti-ccr8 antibody
MX2022008341A (es) 2020-01-06 2022-08-10 Vaccinex Inc Anticuerpos anti-ccr8 y usos de estos.
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
EP4114862A4 (en) 2020-03-05 2024-07-03 Memorial Sloan Kettering Cancer Center Anti-ccr8 agents
JP2023519254A (ja) 2020-03-23 2023-05-10 ブリストル-マイヤーズ スクイブ カンパニー がんを処置するための抗ccr8抗体
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
JP7610302B2 (ja) 2020-08-28 2025-01-08 ハーバー・バイオメド・(シャンハイ)・カンパニー・リミテッド Ccr8抗体及びその用途
WO2022081718A1 (en) 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
KR20230088426A (ko) 2020-10-16 2023-06-19 라노바 메디신즈 리미티드 컴파니 항-ccr8 단클론성 항체 및 그것의 용도
WO2022136647A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Human ccr8 binders
US20240052044A1 (en) 2020-12-24 2024-02-15 Vib Vzw Non-blocking human ccr8 binders

Also Published As

Publication number Publication date
RS66234B1 (sr) 2024-12-31
BR112023024837A2 (pt) 2024-02-20
SMT202400483T1 (it) 2025-01-14
PL4214240T3 (pl) 2025-01-07
JP2023018678A (ja) 2023-02-08
AU2022317803A1 (en) 2023-10-26
EP4491635A2 (en) 2025-01-15
CO2023015915A2 (es) 2023-12-11
MX2023014154A (es) 2024-05-14
SI4214240T1 (sl) 2025-02-28
US20230048553A1 (en) 2023-02-16
TW202321304A (zh) 2023-06-01
HUE069018T2 (hu) 2025-02-28
JP7638935B2 (ja) 2025-03-04
WO2023010054A1 (en) 2023-02-02
EP4214240A1 (en) 2023-07-26
DK4214240T3 (da) 2024-11-18
PT4214240T (pt) 2024-11-25
FI4214240T3 (fi) 2024-11-14
KR20240067052A (ko) 2024-05-16
IL307533A (en) 2023-12-01
CN117425677A (zh) 2024-01-19
CA3220121A1 (en) 2023-02-02
HRP20241561T1 (hr) 2025-02-14
ES2995868T3 (en) 2025-02-11
US11639393B2 (en) 2023-05-02
EP4214240B1 (en) 2024-10-09
AR126578A1 (es) 2023-10-25

Similar Documents

Publication Publication Date Title
SMT202300397T1 (it) Anticorpi contro sars-cov-2
IL289112A (en) Antibodies against tigit
IL291068A (en) Anti-cd73 antibodies
IL284584A (en) Anti-tigit antibodies
IL308741A (en) Anti-SIRP-alpha antibodies
GB202105110D0 (en) Anti-CD73 antibodies
GB201905150D0 (en) Ant-ige antibodies
GB202014851D0 (en) SARS-COV-2 antibodies
LT4214240T (lt) Anti-ccr8 antikūnai
ZA202209699B (en) Novel antibodies
GB201900732D0 (en) Antibodies
GB201917480D0 (en) Antibodies
IL308782A (en) Antibodies
IL308100A (en) Antibodies
GB202111905D0 (en) Antibodies
IL300142A (en) Anti-IL13Ralpha2 antibodies
IL299767A (en) Antibodies against Alpha-4-Beta-7
IL289160A (en) Anti-angpt2 antibodies
GB202015115D0 (en) ZIP12 Antibody
GB2598698B (en) Affinity-maturated anti-ASICIa antibodies
GB202208773D0 (en) Anti-SARS2-S antibodies
IL307175A (en) IL-38 specific antibodies
GB202116709D0 (en) Antibodies
GB202115824D0 (en) Antibodies
GB202112297D0 (en) Antibodies